# Jaguar Animal Health

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/jaguar-animal-health

- Industry: Pharmaceuticals
- Headquarters: San Francisco, US
- Website: www.jaguaranimalhealth.com
- Total disclosed funding: $2M
- Latest round: Series A (Feb 5, 2014)
- Investors on record: 1

## About

Jaguar Animal Health, Inc. focuses on developing and commercializing plant-based prescription medicines to treat gastrointestinal diseases in animals, contributing innovative solutions to improve health outcomes in veterinary care.Jaguar Animal Health, Inc. is dedicated to the development of plant-based medicines for animal health, particularly for gastrointestinal diseases. Founded in 2013, the company is headquartered in San Francisco, US. The firm completed its IPO in May 2015, raising USD 20.02 mn. In March 2017, Jaguar Animal Health merged with Napo Pharmaceuticals, Inc., which bolstered its product offerings with the inclusion of Mytesi (crofelemer 125mg).Jaguar Health specializes in the development and commercialization of plant-based prescription medicines aimed at addressing gastrointestinal (GI) diseases. Their core product, crofelemer, is currently being evaluated in a Phase 3 trial for the preventative treatment of cancer therapy-related diarrhea, demonstrating its therapeutic potential in oncology settings. Additionally, the company supports investigator-initiated proof-of-concept studies of crofelemer for rare diseases such as short bowel syndrome and microvillus inclusion disease. These products are designed to meet unmet medical needs in various regions, including the United States, Europe, and the Middle East/North Africa, with an emphasis on improving patients' quality of life through innovative treatments. The primary end-users of these products include patients undergoing cancer therapies and individuals suffering from rare GI disorders, with a customer base that includes healthcare providers and institutions that prescribe or administer these medications.Jaguar Health's revenue streams are primarily derived from the sales of its plant-based prescription medicines, focusing on securing partnerships and collaborations for research and product development. Transactions typically occur through direct sales to healthcare providers and institutions that utilize their flagship product, crofelemer, in clinical settings. The company also engages in B2B relationships with pharmaceutical distributors and wholesalers that facilitate the delivery of their products to end-users. Given the focus on innovative GI treatments, pricing structures reflect the specialized nature of the medications, tailored to the needs of healthcare facilities and potential insurance reimbursements. Through these channels, Jaguar Health aims to create a sustainable revenue model that supports ongoing research and development while addressing critical health challenges worldwide.Jaguar Animal Health plans to leverage the USD 20.02 mn raised in its IPO for extensive research and development operations focused on upcoming products and market expansion. The company aims to enhance its product portfolio, with additional launches in veterinary gastrointestinal treatments expected in the near term. Furthermore, it seeks to expand into new geographic markets, specifically targeting regions in Europe and the Middle East/North Africa by late 2024. The recent merger with Napo Pharmaceuticals will also facilitate additional revenue streams from Mytesi (crofelemer), allowing Jaguar Health to strengthen its market position and enhance its capabilities in addressing veterinary health challenges.

## Funding rounds

- Series A, Feb 5, 2014, $2M — BVCF Capital

## Investors

- BVCF Capital — Series A